SCHEDULE: Janus Henderson Discloses 9.99% Stake in Ovid Therapeutics

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in Ovid Therapeutics Inc., holding over 7.1 million shares.

Summary

• Janus Henderson Group plc, a Jersey-based investment adviser and parent holding company, has filed a Schedule 13G.
• The filing indicates beneficial ownership of 7,114,114 shares of Ovid Therapeutics Inc. common stock.
• This represents 9.99% of the outstanding class of securities.
• The reported shares include certain pre-funded and/or common warrants.
• An additional 2,303,938 Series A and 2,303,938 Series B common warrants are not reflected in the reported figures due to a self-imposed 9.99% ownership limitation.
• Janus Henderson Group plc holds shared voting power and shared dispositive power over all 7,114,114 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Ovid Therapeutics Inc.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a large, reputable institutional investor has taken a significant stake in Ovid Therapeutics, indicating confidence in the company's prospects. The explicit statement that the investment is not for control purposes also reduces potential uncertainty.

Positives

• A significant institutional investor, Janus Henderson Group plc, has taken a substantial 9.99% stake in Ovid Therapeutics Inc., signaling confidence.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment strategy rather than an activist play.

Negatives

• NA

Risks

• The filing itself does not detail specific risks related to Ovid Therapeutics Inc. beyond the inherent risks of equity investment.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Ovid Therapeutics Inc. or Janus Henderson Group plc regarding Ovid's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant passive investment by a major asset manager, Janus Henderson, in Ovid Therapeutics, a biotechnology company. Such filings are common disclosures when an institutional investor crosses a 5% ownership threshold, providing transparency into large equity positions. For Ovid Therapeutics, a substantial stake by a reputable investment firm can be viewed positively by the market, potentially signaling validation of its long-term prospects within the competitive biotechnology sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• **Shareholders:** The disclosure of a significant institutional stake by Janus Henderson Group plc may instill greater confidence among existing and potential shareholders, potentially leading to increased demand for Ovid Therapeutics' stock.
• **Company Management:** A large institutional investor on the shareholder register may lead to increased scrutiny or engagement from Janus Henderson, though the filing states the investment is passive and not for control.

Next Steps

• NA

Key Dates

Recommendation

The filing indicates a significant institutional investment by Janus Henderson Group plc, which is generally a positive signal for a company like Ovid Therapeutics. However, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial performance data. While the large stake suggests institutional confidence, without additional fundamental information or a change in the company's strategic outlook, a 'hold' recommendation is appropriate for a seasoned investor. This allows for observation of how this significant ownership translates into future company performance or strategic direction, especially given the 9.99% ownership cap and the stated passive nature of the investment.

Keywords

Ovid Therapeutics, Janus Henderson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals, Investment Adviser, Equity Stake